Investigating Mucinase Activity in Airway Disease
Mucinase
2 other identifiers
observational
211
1 country
1
Brief Summary
The purpose of this study is to investigate how mucus (phlegm or spit) is broken down once it forms in the airways (bronchial tubes) of people with lung disease. This research study will also examine whether blood groups have an effect on lung function or the type of mucus found in the lung. This study is not designed to be a treatment for asthma, emphysema, cystic fibrosis, or other lung disease. It is designed to help the investigators learn more about the causes of airway disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2003
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2003
CompletedFirst Submitted
Initial submission to the registry
January 2, 2008
CompletedFirst Posted
Study publicly available on registry
January 16, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedMay 2, 2016
April 1, 2016
12.7 years
January 2, 2008
April 28, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
rheological measurements (viscosity and elasticity) in sputum.
2-3 years
Study Arms (3)
Asthma
People who have been diagnosed with Asthma
Cystic Fibrosis
People who have been diagnosed with Cystic Fibrosis
Healthy
People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
Eligibility Criteria
Volunteers are recruited from community advertisements and health clinics
You may qualify if:
- Asthma:
- Male and female subjects aged 18 - 70 years
- Medical history consistent with asthma
- PC20 (provocative concentration causing a 20% fall) methacholine ≤ 8 mg/ml for subjects not taking inhaled corticosteroids
- PC20 methacholine ≤ 16 mg/ml for subjects taking inhaled corticosteroids
- Ability to provide informed consent
- Cystic Fibrosis:
- Male and female subjects aged 18-55 years
- Prior diagnosis of cystic fibrosis
- Ability to provide informed consent
- Healthy:
- Male and female subjects aged 18-70 years
- No current smoking history
- No history of asthma or allergic rhinitis
- FEV1 (forced expiratory volume in 1 second) \> 80% predicted
- +1 more criteria
You may not qualify if:
- Recent heart attack or stroke
- Known aortic or cerebral aneurysm
- Uncontrolled hypertension
- Pregnancy
- Lactation
- Lung disease other than asthma,cystic fibrosis, or chronic obstructive pulmonary disease (COPD)/emphysema/chronic bronchitis
- Upper- or lower-respiratory tract infection 6 weeks prior to study enrollment
- Significant asthma exacerbation 6 weeks prior to study enrollment
- Increasing hyposensitization therapy for the past 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UCSF Airway Clinical Research Center
San Francisco, California, 94143, United States
Related Links
Biospecimen
Sputum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
John V Fahy, M.D., M.Sc.
University of California, San Francisco
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 2, 2008
First Posted
January 16, 2008
Study Start
April 1, 2003
Primary Completion
December 1, 2015
Study Completion
April 1, 2016
Last Updated
May 2, 2016
Record last verified: 2016-04